Edesa Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EDSA research report →
About the company
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis.
- CEO
- Pardeep Nijhawan
- IPO
- 2010
- Employees
- 16
- HQ
- Markham, ON, CA
Price Chart
- Market Cap
- $66.69M
- P/E
- -5.60
- P/S
- 0.00
- P/B
- 6.07
- EV/EBITDA
- -5.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -82.34%
- ROIC
- -108.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-7,185,523 · -16.46%
- EPS
- $-1.27 · 34.20%
- Op Income
- $-7,911,566
- FCF YoY
- -49.73%
- 52W High
- $20.32
- 52W Low
- $0.72
- 50D MA
- $9.83
- 200D MA
- $4.55
- Beta
- 1.05
- Avg Volume
- 523.78K
Get TickerSpark's AI analysis on EDSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | Nijhawan Pardeep | other | 3,378 |
| Jun 16, 26 | Nijhawan Pardeep | other | 153,550 |
| Jun 1, 26 | Nijhawan Pardeep | other | 1,671 |
| May 27, 26 | Marshall Patrick | other | 19,000 |
| May 27, 26 | MacDonald Sean Arthur | other | 19,000 |
| May 27, 26 | Chypyha Joan | other | 19,000 |
| May 27, 26 | Weiler Peter J. | other | 64,609 |
| May 27, 26 | Brooks Michael J | other | 64,609 |
| May 27, 26 | Sistilli Carlo | other | 19,000 |
| May 27, 26 | Olson Charles V | other | 19,000 |
Our EDSA coverage
Recent articles, reports, and earnings notes.
No research on EDSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EDSA report →Similar companies
Peers in the same neighborhood.